THANK YOU FOR SUBSCRIBING
Medical Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
The new agreement confirms Sebia’s commitment and reaffirms its strategic objective to provide the most advanced diagnostic tools in its fields of expertise.
FREMONT, CA: Sebia, a leader in multiple myeloma diagnostics and monitoring, announces a license agreement with the Erasmus University Medical Center (Erasmus MC) in Rotterdam and the Radboud University Medical Center (Radboudumc) in Nijmegen, The Netherlands. This partnership will allow Sebia to develop a novel clinical laboratory test with minimal residual disease (MRD) status directly on serum samples. The collaboration aims to provide a more accessible and sensitive MRD test for myeloma (MM) patients and conditions.
The main techniques for identifying and quantifying MM biomarkers in clinical practice are powered by serum-protein electrophoresis (SPE), immunofixation, and light chains. These techniques are suggested by the International Myeloma Working Group (IMWG). IMWG guidelines also include other techniques to quantify MRD status, like flow cytometry and next-generation sequencing (NGS). These tests depend on multiple bone marrow (BM) aspirations or biopsies, which shows the risk of non-representative sampling because of a heterogeneous disease pattern. Additionally, BM aspirations and biopsies are invasive and costly.
With the advancement of new and powerful therapies, patients are reaching a full response to treatment. This leads to a need to assess therapy efficiency with more sensitive techniques. The innovation of a serum-based MRD test is an important clinical need for patient care. The latest personalized, targeted mass spectrometry technology proposed by this collaboration is highly sensitive. It enables for assessment of the MRD status directly from patients' sera or Sebias SPE gels.
With personalized diagnostics on one drop of blood, the company can create a patient-friendly alternative to monitor MRD in myeloma patients. This enables dynamic monitoring of patients with responses, which is vital for the early detection of relapse. This essay will support the path towards precision medicine in these patients.
Read Also
